You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)合作夥伴新藥獲有條件批准上市
阿思達克 08-05 08:59
基石藥業(02616.HK)公布,合作夥伴 Blueprint Medicines於7月24日宣布,歐洲藥品管理局人用醫藥產品委員會(CHMP)發布一份積極審查意見,建議有條件批准avapritinib上市,作為一種單藥療法,用於治療攜帶血小板衍生生長因數受體(PDGFRA)D842V突變的不可切除性或轉移性胃腸道間質瘤(GIST)成人患者。

CHMP的審查意見將提交給負責醫藥產品上市許可審批的歐盟委員會做進一步審核。針對avapritinib的上市申請,預計歐盟委員會將在今年9月底前作出最終批復。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account